Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q3FY25 results Revenue Growth: The company reported an 18% increase in revenue from operations for Q3 of the financial year 2024-25, achieving total revenue of Rs 946 crore. Profit Performance: GlaxoSmithKline Pharmaceuticals Limited recorded a Profit After Tax (PAT) of Rs 229 crore for the quarter. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, stated: "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, we continue to strengthen our market presence while ensuring broader access to our medicines and vaccines." Result PDF